Incremental hemodialysis. A therapeutic proposal?
DOI:
https://doi.org/10.18004/anales/2020.053.03.147Keywords:
Incremental Hemodialysis, Residual renal function, Urea clearence, ParaguayAbstract
Several methods are useful to measure renal function (RF). In clinical practice, the creatinina cleareance (CrCl), is widely used, which approximately reflects the glomerular filtration rate (GFR). The 24 hs urine volume collection is required to measure CrCl, however, thanks different formulas we can have a precise CrCl value. The CKD-EPI (chronic kidney disease epidemiology collaboration), is the equation frequently used. According to glomerular filtration rate (GFR), the renal function has been classified in 5 stages. At advances stages (stage 5), (CrCl: 15 ml/min), the patient is faced to receive renal replacement therapy (RRT). Hemodialysis (HD) method is often used. It is carry out 3 times per week (4 hours each).
A 59 years old male, due to the distance between the Capital City and his home, decided to receive HD only two times per week (signed consent). At the beginning of the treatment the patient presents all the clinical and biochemical data corresponding to Chronic Renal Failure stage 5. His diuretic volume (DV), ≥ 1 lt/day. In the case of RF deterioration reflected clinical and/or biochemically, the HD session would be 3 times a week.
At year, presents adequate residual renal function (RRF) and clinics, biochemical parameters as well. If the RRF (measured by urea clareance (Kru) and the DV) decline, 3 sessions per week will be necessary. The RRF maintenance is related to mortality, therefore, its preservation thanks incremental HD, improve the patient survival.
References
1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A et al: Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007, 72 (3): 247 – 259
2. Otero A, de FA, Gayoso P, García F: Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología 2010, 30 (1): 78 – 86
3. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl 3 2013: 1 – 150.
4. Linsay RM, Hernderson LW: Adequacy of dialysis. Kidney Int 23 (suppl 13): S42 – S49, 1983
5. Maduell F, García M, Alcázar R.: Dosificación y adecuación del tratamiento dialítico. Guías SEN: Guías de Centros de hemodiálisis. Nefrología 26 (supl 8): 15 – 21, 2006.
6. Cambi V, Savazzi G, Arisi L.: Short dialysis schedules (SDS) – finally ready to become routine?. Proc Eur Dial Transplant Assoc, 11 (1975), pp: 112 – 120
7. Kalantar – Zadeh K, Casino FG.: Le tus give twice – weekly hemodialysis a chance: Revisiting the taboo. Nephrol Dial Transplant, 29 (2014), pp: 1618 – 1620.
8. National Kidney Foundation. KDOQI clinical practice guidelines and recommendations. Clinical Practice Guidelines for hemodialysis adequacy: 2006. pp. 16 – 21
9. Merino JL, Dominguez P, Bueno B, Amézquita Y, Espejo B, Paraíso V: Aplicación de una pauta de hemodiálisis incremental, basada en la función renal residual, al inicio del tratamiento renal sustitutivo. Nefrología, 37 (2017), pp. 39-46.
10. Teruel Briones JL, Fernández Lucas M, Rivera Gorrin M, Ruiz Roso G, Diaz Dominguez M, Rodriguez Mendiola N, et al: Evolución de la función renal residual con una pauta incremental de diálisis: hemodiálisis frente a diálisis peritoneal. Nefrología, 33 (2013), pp. 640 – 649
11. Zhang M, Wang M, Li H, Yu P, Yuan L, Hao J, Chen Ch, et al.: Association of initial twice – weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. Am J Nephrol, 40 (2014), pp: 140 – 150.
12. Shafi T, Jaar BG, Plantinga LC, Fink NL, Sadler JH, Parekh RS, Powe NR, et al.: Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: For the choices for healthy outcomes in caring for end-stage renal disease (CHOICE) study, Am J Kidney Dis, 56 (2010), pp. 348 – 358.
13. Fernández Lucas M, Teruel JL. Hemodiálisis incremental como formas de inicio de tratamiento sustitutivo renal. Nefrología. Vol: 37 (2017). pp. 1-4
14. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al: Predictors pf loss of residual renal function among new dialysis patients. J Am Soc Nephrol, 11 (2000), pp: 556 – 564.
15. Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K.: Residual renal function improve outcome in incremental hemodialysis despite reduced dialysis dose. Nephrol Dial Transplant, 24 (2009), pp: 2502 – 2510.
16. Casino FG, Basile C.: The variable target model: A paradigm shift in the incremental hemodialysis prescription. Nephrol Dial Transplant, 32 (2017), pp: 182 – 190.
17. Obi Y, Streja E, Rhee CM.: Incremental hemodialysis, residual function, and mortality risk in incident dialysis patients: A cohort study. Am J Kidney Dis, 68 (2016), pp: 256 – 265.
18. Suarez MA, García-Cabrera E, Gascón A, López F, Torregrosa E, García G, Huertas J, de la Flor JC, et al.: Justificación y diseño de DiPPI: un ensayo controlado aleatorizado para evaluar la seguridad y la efectividad de la hemodiálisis progresiva en pacientes incidentes. Nefrología, 38 (2018), pp: 573 – 680.
